Confo Therapeutics, a clinical-stage biotechnology company and a spin-off of VUB and VIB, has been awarded a €1 million grant from Flanders Innovation & Entrepreneurship (VLAIO).
This significant two-year funding will fuel the company's research and development of ultra-long-acting antibody-based therapeutics targeting G-protein coupled receptors (GPCRs). These next-generation antibodies are designed to offer greater efficacy for chronic, lifelong conditions like obesity and other metabolic and endocrine disorders.
Confo Therapeutics' proprietary platform, built on technology developed by VUB professor Jan Steyaert, enables the discovery of novel medicines by stabilizing GPCRs in therapeutically relevant conformations.
The grant will specifically accelerate the development of these novel, long-acting treatments, which aim to overcome the limitations of current peptide-based therapies and deliver meaningful, lasting clinical benefits for patients.